Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC lowered its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 62.7% in the fourth quarter, Holdings Channel reports. The firm owned 9,995 shares of the company’s stock after selling 16,836 shares during the quarter. Calamos Advisors LLC’s holdings in Vaxcyte were worth $818,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Riverview Trust Co acquired a new stake in Vaxcyte during the 3rd quarter worth $27,000. Blue Trust Inc. raised its position in Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares during the last quarter. Meeder Asset Management Inc. raised its position in Vaxcyte by 1,007.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after buying an additional 635 shares during the last quarter. Nomura Asset Management Co. Ltd. purchased a new position in Vaxcyte during the 3rd quarter worth $92,000. Finally, Signaturefd LLC raised its position in Vaxcyte by 51.9% during the 3rd quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock worth $120,000 after buying an additional 358 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on PCVX shares. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $145.71.

Insider Activity

In related news, COO Jim Wassil sold 8,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $92.49, for a total value of $739,920.00. Following the sale, the chief operating officer now directly owns 205,695 shares of the company’s stock, valued at approximately $19,024,730.55. This represents a 3.74 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,616 shares of company stock worth $6,095,681 in the last 90 days. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Stock Up 3.3 %

Shares of PCVX opened at $89.34 on Thursday. The company has a 50-day simple moving average of $87.37 and a 200-day simple moving average of $94.45. The company has a market capitalization of $11.14 billion, a PE ratio of -19.42 and a beta of 0.98. Vaxcyte, Inc. has a 52-week low of $58.10 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter in the previous year, the company posted ($0.91) earnings per share. On average, research analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.